Cambridge BRC

Cardiovascular - Key Publications

  1. Marius M. Hoeper; Robyn J. Barst; Robert C. Bourge; Jeremy Feldman; Adaani E. Frost; Nazzareno Galié; Miguel Angel Gómez-Sánchez; Friedrich Grimminger; Ekkehard Grünig; Paul M. Hassoun; Nicholas W. Morrell; Andrew J. Peacock; Toru Satoh; Gérald Simonneau; Victor F. Tapson; Fernando Torres; David Lawrence; Deborah A. Quinn; and Hossein-Ardeschir Ghofrani, Imatinib Mesylate as Add-On Therapy for Pulmonary Arterial Hypertension: Results of the Randomized IMPRES Study, Circulation, Journal of the American Heart Association, 2013, February, 127:1128-1138

  2. Kaisa M. Mäki-Petäjä, Maysoon Elkhawad, Joseph Cheriyan, Francis R. Joshi, Andrew J.K. Östör, Frances C. Hall, James H.F. Rudd and Ian B. Wilkinson, Anti-Tumor Necrosis Factor-a Therapy Reduces Aortic Inflammation and Stiffness in Patients with Rheumatoid Arthritis, Circulation, Journal of American Heart Association, 2012, October, 112.146092

  3. Joseph Cheriyan; Andrew J. Webb; Lea Sarov-Blat; Maysoon Elkhawad; Sharon M.L. Wallace; Kaisa M. Mäki-Petäjä; David J. Collier; John Morgan; Zixing Fang; Robert N. Willette; John J. Lepore; John R. Cockcroft; Dennis L. Sprecher; Ian B. Wilkinson, Inhibition of p38 Mitogen-Activated Protein Kinase Improves Nitric Oxide–Mediated Vasodilatation and Reduces Inflammation in Hypercholesterolemia, Circulation, Journal of American Heart Association, 2011; 123: 515-523

  4. Maysoon Elkhawad, MBBChir, MA; James H.F. Rudd, MBChB, PhD; Lea Sarov-Blat, PhD; Gengqian Cai, PhD; Richard Wells, BA; L. Ceri Davies, MD, MBBS; David J. Collier, PhD, MBBS; Michael S. Marber, MBBS, PhD; Robin P. Choudhury, BMBCh, MA, DM; Zahi A. Fayad, PhD; Ahmed Tawakol, MD; Fergus V. Gleeson, MBBS; John J. Lepore, MD; Bill Davis, PhD; Robert N. Willette, PhD; Ian B. Wilkinson, BMBCh, DM; Dennis L. Sprecher, MD; Joseph Cheriyan, MBChB. Effects of p38 Mitogen-Activated Protein Kinase Inhibition on Vascular and Systemic Inflammation in Patients With Atherosclerosis, J Am Coll Cardiol Img. 2012; 5(9):911-922. doi:10.1016/j.jcmg.2012.02.016
  5. Albers CA, 16 co-authors, Ouwehand WH. Exome sequencing identifies NBEAL2 as the causative gene for Gray Platelet Syndrome. Nat Genet. 2011;43:735–737.
  6. Calvert PA, Obaid DR, O'Sullivan M, Shapiro LM, McNab D, Densem CG, Schofield PM, Braganza D, ClarkeSC, Ray KK, West NE, Bennett MR. Association Between IVUS Findings and Adverse Outcomes in Patients With Coronary Artery Disease The VIVA (VH-IVUS in Vulnerable Atherosclerosis) Study. JACC Cardiovasc Imaging. 2011;4:894-901.
  7. Gieger C*, 129 co-Authors, Ouwehand WH* & Soranzo N* (2011) New gene functions in megakaryopoiesis and platelet formation. Nature 2011;480:201-208.
  8. Albers CA, 28 co-authors, Ouwehand WH*, Ghevaert C*. Compound inheritance of a low-frequency regulatory SNP and a rare null mutation in exon-junction complex subunit RBM8A causes TAR syndrome. Nat Genet. 2012; 44:435-439.
  9. Ormiston ML, Chang C, Long LL, Soon E, Jones D, Machado R, Treacy C, Toshner MR, Campbell K, Riding A, Southwood M, Pepke-Zaba J, Exley A, Trembath RC, Colucci F, Wills M, Trowsdale J, Morrell NW. Impaired Natural Killer Cell Phenotype and Function in Idiopathic and Heritable Pulmonary Arterial Hypertension. Circulation. 2012 [Epub ahead of print].
  10. Obaid D, Calvert P, McNab D, West N, Bennett M. Identification of vulnerable coronary plaques using Virtual histology intravascular ultrasound (VH-IVUS) is affected by inter-observer variability and differences in plaque definitions. Circ Cardiovasc Imaging. 2012;5:86-93
  11. Cheung C, Bernardo AS, Trotter MW, Pedersen RA and Sinha S. Generation of human vascular SMC subtypes provides insights into embryological origin-dependent disease susceptibility. Nature Biotech 2012;30:165-73.
  12. Dweck M, Chow MW, Joshi NV, Williams MC, Jones C, Fletcher AM, Richardson H, White A, McKillop G, van Beek EJ, Boon NA, Rudd JHF*, Newby DE* (*Joint Senior Authors) Coronary Arterial NaF uptake: a novel marker of plaque biology. J Am Coll Cardiol 2012;59:1539-48.
  13. Khan FZ, Virdee MS, Palmer CR, Pugh PJ, O'Halloran D, Elsik M, Read PA, Begley D, Fynn SP, Dutka DP. Targeted left ventricular lead placement to guide cardiac resynchronization therapy: the TARGET study: a randomized, controlled trial. J Am Coll Cardiol. 2012;59:1509-18.
Rightnav: 
Highlights Vulnerable Plaque Imaging The cardiovascular PET programme examines non-invasive measurement of inflammation, hypoxia and other markers of high-risk atherosclerotic plaque disease. The BRC has funded a trainee vascular surgeon who is supervising 2 ongoing translational research studies. One prospective study is investigating the determinants of aortic aneurysm expansion over a 3-year period, hypothesising that inflammation, hypoxia or neovascularisation detected by PET/CT or MRI at baseline is predictive of future aneurysm expansion. Read more...